Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Work
Year: 2016
Type: article
Abstract: A patient with recurrent multifocal glioblastoma received chimeric antigen receptor (CAR)-engineered T cells targeting the tumor-associated antigen interleukin-13 receptor alpha 2 (IL13Rα2). Multiple ... more
Source: New England Journal of Medicine
Institutions CTI BioPharma (United Kingdom), City of Hope, Beckman Research Institute, City Of Hope National Medical Center, Seattle Children's Hospital
Cites: 25
Cited by: 1,575
Related to: 10
FWCI: 65.45
Citation percentile (by year/subfield): 100
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: bronze